Literature DB >> 2859077

Amphetamine, mazindol, and fencamfamin in narcolepsy.

J Shindler, M Schachter, S Brincat, J D Parkes.   

Abstract

Twenty patients with the narcoleptic syndrome were treated separately with dexamphetamine sulphate tablets 10 and 30 mg, Dexedrine Spansules 10 mg, mazindol 4 mg, and fencamfamin hydrochloride 60 mg daily. Each drug was given for four weeks and the effects compared. In these dosages the reported frequency of attacks of narcolepsy was roughly halved with each treatment, dexamphetamine 30 mg daily being only slightly more potent than 10 mg. The subjective effects of Dexedrine tablets and Spansules could not be distinguished by most patients. Effects on mood, alertness, and sympathomimetic side effects were largely inseparable with all these drugs, but a decrease in appetite was not reported by patients with narcolepsy.

Entities:  

Mesh:

Substances:

Year:  1985        PMID: 2859077      PMCID: PMC1418853          DOI: 10.1136/bmj.290.6476.1167

Source DB:  PubMed          Journal:  Br Med J (Clin Res Ed)        ISSN: 0267-0623


  13 in total

1.  INFLUENCE OF URINARY PH ON EXCRETION OF AMPHETAMINE.

Authors:  A H BECKETT; M ROWLAND; P TURNER
Journal:  Lancet       Date:  1965-02-06       Impact factor: 79.321

2.  A single dose study of trazodone with an assessment of its effect on mood and arousal.

Authors:  B Munday; M J Kendall; M Mitchard
Journal:  Br J Clin Pharmacol       Date:  1975-02       Impact factor: 4.335

3.  AN. 448 on critical flicker frequency and heart rate in man.

Authors:  A Hedges
Journal:  S Afr Med J       Date:  1972-02-05

4.  The sleep-waking cycle.

Authors:  G Moruzzi
Journal:  Ergeb Physiol       Date:  1972

5.  Suppression of renal excretion of fencamfamine in man.

Authors:  T B Vree; J M van Rossum
Journal:  Eur J Pharmacol       Date:  1969-08       Impact factor: 4.432

6.  Subjective effects of two anorexigenic agents--fenfluramine and AN 448 in normal subjects.

Authors:  J Holmstrand; J Jonsson
Journal:  Postgrad Med J       Date:  1975       Impact factor: 2.401

Review 7.  Treating problem children with stimulant drugs.

Authors:  L A Sroufe; M A Stewart
Journal:  N Engl J Med       Date:  1973-08-23       Impact factor: 91.245

8.  Pharmacological analysis of a new anorexic substance: 5-hydroxy-5(4'-chlorophenyl)-2, 3-dihydro-5H-imidazo-(2, 1-a) isoindole (Mazindol).

Authors:  J H Gogerty; C Penberthy; L C Iorio; J H Trapold
Journal:  Arch Int Pharmacodyn Ther       Date:  1975-04

Review 9.  Anorectic drugs: use in general practice.

Authors:  D Craddock
Journal:  Drugs       Date:  1976       Impact factor: 9.546

10.  Mazindol in the treatment of narcolepsy.

Authors:  J D Parkes; M Schachter
Journal:  Acta Neurol Scand       Date:  1979-10       Impact factor: 3.209

View more
  8 in total

1.  Narcolepsy.

Authors:  M R Allsopp; Z Zaiwalla
Journal:  Arch Dis Child       Date:  1992-03       Impact factor: 3.791

Review 2.  Pharmacology of stimulants prohibited by the World Anti-Doping Agency (WADA).

Authors:  J R Docherty
Journal:  Br J Pharmacol       Date:  2008-06       Impact factor: 8.739

Review 3.  Treatment Options for Narcolepsy.

Authors:  Lucie Barateau; Régis Lopez; Yves Dauvilliers
Journal:  CNS Drugs       Date:  2016-05       Impact factor: 5.749

Review 4.  Drug treatment of patients with insomnia and excessive daytime sleepiness: pharmacokinetic considerations.

Authors:  S Nishino; E Mignot
Journal:  Clin Pharmacokinet       Date:  1999-10       Impact factor: 6.447

5.  Treatment of central disorders of hypersomnolence: an American Academy of Sleep Medicine systematic review, meta-analysis, and GRADE assessment.

Authors:  Kiran Maski; Lynn Marie Trotti; Suresh Kotagal; R Robert Auger; Todd J Swick; James A Rowley; Sarah D Hashmi; Nathaniel F Watson
Journal:  J Clin Sleep Med       Date:  2021-09-01       Impact factor: 4.324

Review 6.  Management of Narcolepsy.

Authors:  Lucie Barateau; Régis Lopez; Yves Dauvilliers
Journal:  Curr Treat Options Neurol       Date:  2016-10       Impact factor: 3.598

Review 7.  Treatment of Excessive Daytime Sleepiness in Patients with Narcolepsy.

Authors:  Laura Pérez-Carbonell
Journal:  Curr Treat Options Neurol       Date:  2019-11-12       Impact factor: 3.598

8.  Narcolepsy: current treatment options and future approaches.

Authors:  Michel Billiard
Journal:  Neuropsychiatr Dis Treat       Date:  2008-06       Impact factor: 2.570

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.